Lung Cancer Clinical Trials

LUNG CANCER OBSERVATIONAL: (1)
*SMALL CELL LUNG CANCER
1) JAZZ/ EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients with Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca.

LUNG CANCER: (5)
*NON-SMALL CELL LUNG CANCER
1) Neoadjuvant Setting for Resectable patients Stage IIA to select Stage IIIB/ USO#19211 AEGEAN: A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer

2) Untreated Locally Advanced (Stage 3A, 3B, or 3C) Amendable to CCRT/ BMS CA209-73L: A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-Small Cell Lung Cancer (LA NSCLC)

3) USO#19151 MRTX891-0001: A Phase ½ Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation- Multiple cohorts

4) USO #19118 CARMEN-LC03 Randomized, Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated metastatic non-squamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors

5) RMC-4630-03- A Phase 2, Open-Label, Mulitcenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS(G12C) Mutation After Failure of Prior Standard Therapies. Evaluate the antitumor effects of RMC-4630 and Sotorasib as assessed by objective response rate per RECIST v1.1 in locally advanced or metastatic NSCLC subjects with KRASG12C mutation with and without co-existing genetic aberrations in specific genes such as STK11/LKB1, KEAP1, and PIK3CA after failure of prior standard therapy. (No more than 3 prior lines of therapy)

Send UsA Message

    Call Now Button